HALO — Halozyme Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.79bn
- $15.71bn
- $1.40bn
Halozyme rises as Vertex signs global drug delivery tech deal
Brief: Halozyme Announces Global Collaboration And License Agreement With Vertex Pharmaceuticals For Hypercon™ Technology
Brief: U.S. FDA Approves Tecvayli® In Combination With Darzalex Faspro® For Relapsed/Refractory Multiple Myeloma
Brief: Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million
Halozyme 2025 revenue up 38%, Q4 EPS misses estimates
Corrected: BRIEF-Halozyme Therapeutics Q4 Adjusted EPS USD -0.24 Vs. IBES Estimate USD 2.2
Brief: Halozyme Raises 2025 Revenue Estimates, Raises 2026 And Multi-Year Financial Guidance
Brief: Halozyme Announces Global Collaboration And License Agreement With Takeda
U.S. RESEARCH ROUNDUP- Alcoa, BlackRock, Evercore
Skye Bioscience rises as it partners with Halozyme on obesity drug
Brief: U.S. FDA Approves Rybrevant Faspro™ For The Treatment Of Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Brief: Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC In Germany
Brief: Halozyme Completes Acquisition Of Elektrofi, Expanding Breadth Of Offerings In Drug Delivery
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab
U.S. STOCKS ON THE MOVE-Akamai Technologies, Enbridge, KKR
Halozyme Therapeutics down after $1.3 bln convertible bonds sale
Brief: FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
Halozyme Therapeutics dips after unveiling $1.3 bln convertible bonds sales
Drug delivery firm Halozyme's Q3 adjusted EPS beats estimates